Use of botulinum toxin in urology: a literature  review : Ürolojide botulinum toksin uygulamaları: literatür derlemesi

Ömer Bayrak; İlker Seçkiner; Rahmi  Onur; Roger Roman Dmochowski

doi:10.5152/EurJTher.2017.163

Authors

Ömer Bayrak Department of Urology, Gaziantep University School of Medicine
İlker Seçkiner Department of Urology, Gaziantep University School of Medicine
Rahmi Onur Department of Urology, Marmara University School of Medicine
Roger Roman Dmochowski Department of Urology, Vanderbilt University Medical Center

DOI:

https://doi.org/10.5152/EurJTher.2017.163

Keywords:

Botulinum toxin, neurogenic detrusor overactivity, overactive bladder, detrusor sphincter dyssynergia, benign prostatic enlargement, interstitial cystitis

Abstract

Botulinum neurotoxin (BoNT) is currently preferred as a minimally invasive treatment for lower urinary tract pathologies. Although BoNT injections have become widespread globally for the past 5 years, today, the urological use of BoNT Type A (BoNT-A) is only licensed for the treatment of neurogenic detrusor overactivity and overactive bladder. Despite the relative evidence for the use of BoNT-A in benign prostatic enlargement, there is no high-level evidence data for the use in detrusor sphincter dyssynergia, interstitial cystitis/bladder pain syndrome, and chronic pelvic pain. In this comprehensive review, we mention the mechanism of action and efficacy of BoNT in various urological disorders, present the reliability, and evaluate the literature data supporting its use.

Metrics

Metrics Loading ...

References

Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmo¬dic torticollis: dysphagia and regional toxin spread. Head Neck 1990; 12: 392-9.

Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439-46.

Thwaini A, Shergill I, Radhakrishnan S, Chinegwundoh F, Thwaini H. Botox in urology. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 536-40.

Schantz E, Johnson E. Preparation and characterization of botulinum toxin type A for human treatment. Jankovic J, editor. Neurological Disease and Therapy. New York; Marcel Dekker Inc; 1994. p. 41-9.

Scott AB, Rosenbaum A, Collins CA. Pharmacologic weakening of extraocular muscles. Invest Ophtalmol Vis Sci 1973; 12: 924-7.

Scott AB. Botulinum toxin injection of eyemuscles to correct strabismus. Trans Am Ophtalmol Soc 1981; 79: 734-70.

Dressler D, Bigalke H. Pharmacology of botulinum toxin drugs. Truong D, Dressler D, Hallett M, editors. Manual of Botulinum Toxin Therapy. New York; Cambridge University Press; 2009. pp. 13-22.

Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919-22.

Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000: 164; 692-7.

Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014; 65: 981-90.

Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, et al. EAU Guidelines on Urinary Incontinence in Adults. European Association of Urology 2017.

Moore DC, Cohn JA, Dmochowski RR. Use of botulinum toxin a in the treatment of lower urinary tract disorders: a review of the literature. Toxins (Basel) 2016; 8: 88.

Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997; 49: 189-94.

Anki KR. Pharmacology and immunology of botulinum toxinserotypes. J Neurol 2001; 248: 3-10.

Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhães M, Correia AP, et al. DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—Assuming a ratio of 4:1. Mov Disord 1997; 12: 1013-8.

Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: A double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatr 2002; 72: 459-62.

Rossetto O, Seveso M, Caccin P, Schiavo G, Monte¬cucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 2001; 39: 27-41.

Demirtas A, Onur R. İnkontinans Tedavisinde Botulinum Toksin Uygulamaları. Onur R, Bayrak O, editors. Üriner İnkontinans: Tanı ve Tedavi. Istanbul; Nobel Tıp Kitabevleri; 2015. pp. 237-54.

Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendation on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic flor dysfunctions: A European consensus report. Eur Urol 2009; 55: 100-19.

Davis NF, Burke JP, Redmond EJ, Elamin S, Brady CM, Flood HD. Trigonal versus extratrigonal botulinum toxin-A: A systematic review and meta-analysis of efficacy and adverse events. Int Urogynecol J 2015; 26: 313-9.

Rapp DE, Lucioni A, Katz EE, O’Connor RC, Gerber GS, Bales GT. Use of botulinum toxin-A for the treatment of refractory overactivite bladder symptoms: an initial experience. Urology 2004; 63: 1071-5.

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14.

Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. American Urological Association.; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188: 2455-63.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized,

placebo control¬led trial. J Urol 2013; 189: 2186-93.

Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012; 62: 507-14.

Onem K, Bayrak O, Demirtas A, Coskun B, Dincer M, Kocak I, et al. Turkish Urology Academy, Incontinence/Neurourology Study Group. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population. Neurourol Urodyn. 2017 Apr 13. doi: 10.1002/nau.23286. [Epub ahead of print].

Leong Randall K, De Wachter Stefan GG, van Kerrebroeck Philip EV. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 2010; 84: 245-53.

Lawrence GW, Aoki KR, Dolly JO. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers. J Pharmacol Exp Ther 2010; 334: 1080-6.

Cruz F, Guimaraes M, Silva C, Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997; 350: 640-1.

Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665.

Ginsberg D, Gousse A, Keppenne, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of Onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012; 187: 2131-9.

Deffontaines-Rufin S, Weil M, Verollet D, Peyrat L, Amarenco G. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol 2011; 37: 642-8.

Blok B, Pannek J, Castro-Diaz D, del Popolo G, Groen J, Hamid R, et al. EAU Guidelines on Neuro-Urology. European Association of Urology 2017.

Koziol JA. Epidemiology of interstitial cystitis. Urol Clin North Am 1994; 21: 7.

Hanno PM, Erickson D, Moldwin R, Faraday MM. American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol 2015; 193: 1545-53.

Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 2008; 179: 1031-4.

Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 2009; 104: 657-61.

Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn 2016; 35: 609-14.

Kilicarslan H, Ayan S, Vuruskan H, Gokce G, Gultekin EY. Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin. Int Urol Nephrol 2006; 38: 537-41.

Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum-A toxin: a double-blind study. Arch Phys Med Rehabil 1990; 71: 24-6.

Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996; 155: 1023-9.

Schurch B, Schmid DM, Knapp P. An update on the treatment of detrusor-sphincter dyssynergia with botulinum toxin type A. Eur J Neurol 1999; 6: 83-9.

Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-cont¬rolled study. Urology 2003; 62: 259-64.

Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with be¬nign prostatic hyperplasia. BJU Int 2006; 98: 1033-7.

Guercini F, Giannantoni A, Bard RL, Brisinda G, Cadeddu F, Maria G, et al. Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia: a multicenter feasibility study. J Urol 2005; 173: 376-7.

Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK. Evalution of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 2006; 47: 706-14.

Gravas S, Bach T, Drake M, Gacci M, Gratzke C, Herrmann TRW, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology 2017.

Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236-7.

Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62: 259-64.

Zermann D, Ishigooka M, Schubert J, Schmidt RA. Perisphincteric injection of botulinum toxin type A - A treatment option for patients with chronic prostatic pain? Eur Urol 2000; 38: 393-9.